Drug-related problems in hospitalized oncology patients, with special focus on r...

연구 요약

Drug-related problems in hospitalized oncology patients, with special focus on radiotherapy units: Implications for oncology pharmacy practice.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 학술지에 발표된 이 연구는 Regulska K, Michalak M, Janiszewska B 외 연구팀이 수행하였습니다.

이 연구는 'Drug-related problems in hospitalized oncology patients, with special focus on radiotherapy units: Implications for oncology pharmacy practice.'에 대한 과학적 분석을 제공합니다.

핵심 내용

IntroductionDrug-related problems (DRPs) represent a major challenge in contemporary oncology. In healthcare systems with limited clinical pharmacy resources, identification of high-risk patient groups and treatment settings is - from a clinical pharmacology perspective - essential to prioritize pharmacotherapeutic surveillance.MethodsThis single-centre, retrospective, high-risk cohort study analysed pharmacotherapy in 31 adult cancer patients hospitalized in a comprehensive oncology centre in Poland. Patients were selected for medication review based on clinicians' suspicion of pharmacotherapy-related problems during hospitalization. DRPs were identified and classified according to the Pharmaceutical Care Network Europe classification version 9.1, focusing on pharmacotherapy-related complications rather than individual prescribing errors. Sociodemographic, clinical and pharmacotherapeutic variables were analysed. Statistical analyses were exploratory and hypothesis-generating.ResultsAt least one DRP was identified in 29 out of 31 patients (94%). The most frequent DRPs were adverse drug reactions and drug therapy without a clearly documented current indication, predominantly involving proton pump inhibitors (PPIs). Antimicrobials, drugs for acid-related disorders and psycholeptics accounted for the highest number of DRPs. A numerically higher risk of DRPs was observed in patients with impaired renal function, excessive polypharmacy (≥ 10 drugs) and those receiving non-surgical treatment, particularly radiotherapy.ConclusionHospitalized oncology patients with suspected pharmacotherapy-related complications are at high risk of DRPs. From an oncology pharmacy perspective, targeted medication review appears to be a rational approach to identify and mitigate pharmacotherapy-related risks in this setting. Radiotherapy units, patients with impaired renal function, antimicrobials and PPI use or extensive polypharmacy represent priority areas for enhanced clinical pharmacy involvement.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41761490)